We are live on ! Find out more
PNT

POINT Biopharma Global Inc. Common Stock
PNT

Delisted

PNT was delisted on the 26th of December, 2023.

Back to rankings

68 hedge funds and large institutions have $316M invested in POINT Biopharma Global Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 24 increasing their positions, 9 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

217% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 6

167% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 9

63% more capital invested

Capital invested by funds: $194M → $316M (+$122M)

24% more funds holding

Funds holding: 55 → 68 (+13)

Holders
68
Holders Change
+13
Holders Change %
+23.64%
% of All Funds
1.07%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
19
Increased
24
Reduced
9
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
GPP
Great Point Partners
Connecticut
+$11.9M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$11.3M
3
FFM
Fairmount Funds Management
Pennsylvania
+$5.04M
4
Millennium Management
Millennium Management
New York
+$3.58M
5
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$3.46M

Top Sellers

Rank Fund Capital Flow
1
FCM
Farallon Capital Management
California
-$6.86M
2
Franklin Resources
Franklin Resources
California
-$4.33M
3
SFM
Sphera Funds Management
Israel
-$3.32M
4
LP
LMR Partners
United Kingdom
-$343K
5
Goldman Sachs
Goldman Sachs
New York
-$288K
Name Holding Trade Value Shares
Change 		Change in
Stake
Squarepoint
26
Squarepoint
New York
$867K +$691K +108,792 New
Goldman Sachs
27
Goldman Sachs
New York
$686K -$288K -45,431 -35%
Swiss National Bank
28
Swiss National Bank
Switzerland
$679K +$36.8K +5,800 +7%
AI
29
Atom Investors
Texas
$479K +$273K +43,007 +252%
Jane Street
30
Jane Street
New York
$378K +$301K +47,366 New
Bank of Montreal
31
Bank of Montreal
Ontario, Canada
$355K +$279K +44,000 New
D.E. Shaw & Co
32
D.E. Shaw & Co
New York
$349K -$250K -39,308 -47%
Point72 Asset Management
33
Point72 Asset Management
Connecticut
$337K +$268K +42,268 New
Marshall Wace
34
Marshall Wace
United Kingdom
$304K +$211K +33,240 +683%
Balyasny Asset Management
35
Balyasny Asset Management
Illinois
$283K +$226K +35,565 New
California State Teachers Retirement System (CalSTRS)
36
California State Teachers Retirement System (CalSTRS)
California
$276K +$25.6K +4,035 +13%
N
37
Nuveen
North Carolina
$271K +$266K +41,817 New
CSS
38
Cubist Systematic Strategies
Connecticut
$270K +$215K +33,896 New
FWP
39
Firethorn Wealth Partners
Georgia
$269K +$13K +2,050 +6%
SM
40
Sciencast Management
New Jersey
$256K +$206K +32,368 New
State of Wisconsin Investment Board
41
State of Wisconsin Investment Board
Wisconsin
$238K +$190K +29,900 New
Charles Schwab
42
Charles Schwab
California
$232K – – –
Bank of New York Mellon
43
Bank of New York Mellon
New York
$230K – – –
MFS
44
Mirabella Financial Services
United Kingdom
$207K +$71.9K +11,320 +77%
CS
45
Credit Suisse
Switzerland
$184K +$9.57K +1,507 +7%
CCP
46
Clarkston Capital Partners
Michigan
$180K – – –
JP Morgan Chase
47
JP Morgan Chase
New York
$160K -$103K -16,227 -45%
UBS AM
48
UBS AM
Illinois
$145K – – –
YIH
49
Y-Intercept (HK)
Hong Kong
$140K +$112K +17,568 New
CA
50
Claro Advisors
Massachusetts
$130K – – –
1
2
3

PNT Hedge Fund Activity: Q1 2022 in Review

68 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in POINT Biopharma Global Inc. Common Stock (PNT) for Q1 2022, worth a combined $316M — up 63% from $194M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new PNT positions and 6 closed out — a net gain of 13 holders — while 24 added to existing stakes and 9 trimmed.

The largest buyer was Great Point Partners, adding an estimated $11.9M. The largest seller was Farallon Capital Management, cutting an estimated $6.86M.

  • 68 institutional investors held POINT Biopharma Global Inc. Common Stock (PNT) as of Q1 2022, up from 55 in Q4 2021.
  • Funds reported $316M of POINT Biopharma Global Inc. Common Stock stock for Q1 2022, up 63% quarter-over-quarter.
  • 19 funds opened new POINT Biopharma Global Inc. Common Stock positions in Q1 2022 and 6 closed out, a net change of +13 holders.
  • The largest POINT Biopharma Global Inc. Common Stock buyer in Q1 2022 was Great Point Partners, an estimated $11.9M added.
  • The largest POINT Biopharma Global Inc. Common Stock seller in Q1 2022 was Farallon Capital Management, an estimated $6.86M sold.

Based on aggregated 13F filings for Q1 2022.